Market Cap 283.08M
Revenue (ttm) 41.02M
Net Income (ttm) 2.92M
EPS (ttm) N/A
PE Ratio 58.42
Forward PE 42.99
Profit Margin 7.12%
Debt to Equity Ratio 0.00
Volume 48,700
Avg Vol 68,552
Day's Range N/A - N/A
Shares Out 18.97M
Stochastic %K 71%
Beta 1.23
Analysts Strong Sell
Price Target $18.20

Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitatio...

Industry: Medical Devices
Sector: Healthcare
Phone: 972 2 582 4030
Address:
16 Hartum St, Har Hotzvim, Jerusalem, Israel
NVDAMillionaire
NVDAMillionaire Oct. 3 at 11:01 AM
$BWAY Brilliant piece that captures BWAY's situation perfectly. So if you want to update your understanding of BWAY or get to know BWAY better, this is essential reading. https://beyondspx.com/quote/BWAY/analysis/brainsway-s-deep-dive-into-growth-expanding-reach-and-innovation-in-neurostimulation-nasdaq-bway
0 · Reply
highnihilism
highnihilism Oct. 1 at 12:28 PM
$BWAY Brainsway Trades: 2 | Total $: 365 | 0.12 × 90-Day Avg $: 3.1 K | Call $: 365 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $IAI U.S. Broker-Dealers & Securities Exchanges ETF Trades: 1 | Total $: 360 | 0.04 × 90-Day Avg $: 10 K | Call $: 360 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $HRTX Heron Therapeutics Trades: 5 | Total $: 359 | 0.02 × 90-Day Avg $: 15.6 K | Call $: 359 | Put $: 0 | Single-Leg: 93% | Multi-Leg: 7% | Contingent: – $ANVS Annovis Bio Trades: 17 | Total $: 558 | 0.07 × 90-Day Avg $: 8.4 K | Call $: 358 | Put $: 200 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
BroadwayBrokers
BroadwayBrokers Sep. 28 at 7:33 PM
$BWAY Sales are high and cash flow is strong. Leadership seems legit. FDA approval OTW.
0 · Reply
BrainsWay
BrainsWay Sep. 25 at 7:28 PM
$BWAY BrainsWay CEO on FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of MDD “More than just another clearance, this marks a pivotal advancement in the treatment of depression with Deep TMS because it expands the ways in which we can use Deep TMS to treat depression. While previously, treatment involved 4 weeks of daily treatment sessions before follow up visits, this newly cleared accelerated protocol includes an acute phase of just 6 treatment days.” Quote from Hadar Levy, CEO of BrainsWay
1 · Reply
BrainsWay
BrainsWay Sep. 18 at 5:01 PM
$BWAY BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD) This breakthrough gives patients a faster and non-invasive pathway to relief with no fMRI neuro-navigation required. We are proud to advance the accessibility of mental health care worldwide. 🔗 Read the full announcement here: https://www.brainsway.com/news_events/brainsway-receives-fda-clearance-for-accelerated-deep-tms-protocol-for-non-invasive-treatment-of-major-depressive-disorder-mdd/ #BrainsWay #BWAY #IR #Neurotech #DeepTMS #Growth
0 · Reply
ZacksResearch
ZacksResearch Sep. 17 at 5:03 PM
$BWAY surges 11.9% on FDA clearance! 🚀 The new accelerated TMS protocol for depression is a game-changer, reducing treatment time significantly and boosting accessibility. This positions BrainsWay to capture more of the mental health market, driving strong growth potential. Discover the full impact here 👉 https://www.zacks.com/stock/news/2752844/bway-shares-gain-on-fda-nod-for-accelerated-deep-tms-depression-care?cid=sm-stocktwits-2-2752844-body-12865&ADID=SYND_STOCKTWITS_TWEET_2_2752844_BODY_12865
0 · Reply
ZacksResearch
ZacksResearch Sep. 17 at 4:03 PM
$BWAY popping on FDA green light 🚀🧠 Shares jumped after approval of its accelerated Deep TMS protocol, delivering faster depression care backed by strong clinical results. See the full details here 👉 https://www.zacks.com/stock/news/2752844/bway-shares-gain-on-fda-nod-for-accelerated-deep-tms-depression-care?cid=sm-stocktwits-2-2752844-teaser-12855&ADID=SYND_STOCKTWITS_TWEET_2_2752844_TEASER_12855
0 · Reply
notreload_ai
notreload_ai Sep. 16 at 4:13 PM
$BWAY has received FDA clearance for a new Deep TMS protocol, providing a non-invasive treatment for Major Depressive Disorder. This method targets deep brain areas to reduce treatment times. https://notreload.xyz/brainsway-deep-tms-accelerated-depression-treatment-approved/
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 16 at 12:42 PM
$BWAY (+3.0% pre) BrainsWay gets FDA clearance for accelerated depression treatment protocol https://ooc.bz/l/77430
0 · Reply
BrainsWay
BrainsWay Sep. 16 at 8:01 AM
$BWAY 📊 BrainsWay by the Numbers: Strong Fundamentals for Growth BrainsWay (NASDAQ: BWAY) continues to advance its leadership in Deep TMS™ with solid financial guidance and a growing clinical and commercial footprint: • ~$52M Revenue (2025 guidance) • 75% Gross Margin (2025 guidance) • $7M Adjusted EBITDA (2025 guidance) • $78M Cash Balance (as of Q2 2025) • $62M Signed Backlog (Q2 2025) • 1,522 Total Installed Base (as of Q2 2025) • 880 OCD Systems (as of Q2 2025) • 6.3M Deep TMS™ Treatments delivered to 220K+ patients • 35+ Completed Clinical Trials with 360+ publications Each new deal BrainsWay has with leading mental health providers has the potential to add $10–15M in RPO with no additional operational expense, accelerating both top-line growth and margins. #BrainsWay #BWAY #InvestorRelations #Neurotech #DeepTMS
0 · Reply
Latest News on BWAY
BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 3:21 PM EDT - 7 weeks ago

BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript


BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:16 AM EDT - 5 months ago

BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript


BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 10:17 AM EDT - 7 months ago

BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript


BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 12:59 PM EST - 11 months ago

BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript


BrainsWay Announces Significant Expansion on U.S. East Coast

Sep 16, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Announces Significant Expansion on U.S. East Coast


BrainsWay Appoints Richard A. Bermudes, M.D.

Aug 29, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Appoints Richard A. Bermudes, M.D.


BrainsWay: Operating Leverage Driving Upside

Aug 13, 2024, 4:40 AM EDT - 1 year ago

BrainsWay: Operating Leverage Driving Upside


BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 12:03 PM EDT - 1 year ago

BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript


BrainsWay: Cash Flows Are Underappreciated

May 9, 2024, 9:00 AM EDT - 1 year ago

BrainsWay: Cash Flows Are Underappreciated


BrainsWay Ltd. (BWAY) Q1 2024 Earnings Call Transcript

May 8, 2024, 1:16 PM EDT - 1 year ago

BrainsWay Ltd. (BWAY) Q1 2024 Earnings Call Transcript


BrainsWay Ltd. (BWAY) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 10:04 AM EST - 1 year ago

BrainsWay Ltd. (BWAY) Q4 2023 Earnings Call Transcript


BrainsWay: Positive Cash Flow And Continued Growth

Nov 20, 2023, 12:01 AM EST - 2 years ago

BrainsWay: Positive Cash Flow And Continued Growth


Brainsway Ltd (BWAY) Q3 2023 Earnings Call Transcript

Nov 15, 2023, 2:52 PM EST - 2 years ago

Brainsway Ltd (BWAY) Q3 2023 Earnings Call Transcript


BrainsWay: Profitability Is Within Sight

Aug 10, 2023, 4:07 PM EDT - 2 years ago

BrainsWay: Profitability Is Within Sight


Brainsway Ltd (BWAY) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 1:29 PM EDT - 2 years ago

Brainsway Ltd (BWAY) Q2 2023 Earnings Call Transcript


NVDAMillionaire
NVDAMillionaire Oct. 3 at 11:01 AM
$BWAY Brilliant piece that captures BWAY's situation perfectly. So if you want to update your understanding of BWAY or get to know BWAY better, this is essential reading. https://beyondspx.com/quote/BWAY/analysis/brainsway-s-deep-dive-into-growth-expanding-reach-and-innovation-in-neurostimulation-nasdaq-bway
0 · Reply
highnihilism
highnihilism Oct. 1 at 12:28 PM
$BWAY Brainsway Trades: 2 | Total $: 365 | 0.12 × 90-Day Avg $: 3.1 K | Call $: 365 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $IAI U.S. Broker-Dealers & Securities Exchanges ETF Trades: 1 | Total $: 360 | 0.04 × 90-Day Avg $: 10 K | Call $: 360 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $HRTX Heron Therapeutics Trades: 5 | Total $: 359 | 0.02 × 90-Day Avg $: 15.6 K | Call $: 359 | Put $: 0 | Single-Leg: 93% | Multi-Leg: 7% | Contingent: – $ANVS Annovis Bio Trades: 17 | Total $: 558 | 0.07 × 90-Day Avg $: 8.4 K | Call $: 358 | Put $: 200 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
BroadwayBrokers
BroadwayBrokers Sep. 28 at 7:33 PM
$BWAY Sales are high and cash flow is strong. Leadership seems legit. FDA approval OTW.
0 · Reply
BrainsWay
BrainsWay Sep. 25 at 7:28 PM
$BWAY BrainsWay CEO on FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of MDD “More than just another clearance, this marks a pivotal advancement in the treatment of depression with Deep TMS because it expands the ways in which we can use Deep TMS to treat depression. While previously, treatment involved 4 weeks of daily treatment sessions before follow up visits, this newly cleared accelerated protocol includes an acute phase of just 6 treatment days.” Quote from Hadar Levy, CEO of BrainsWay
1 · Reply
BrainsWay
BrainsWay Sep. 18 at 5:01 PM
$BWAY BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD) This breakthrough gives patients a faster and non-invasive pathway to relief with no fMRI neuro-navigation required. We are proud to advance the accessibility of mental health care worldwide. 🔗 Read the full announcement here: https://www.brainsway.com/news_events/brainsway-receives-fda-clearance-for-accelerated-deep-tms-protocol-for-non-invasive-treatment-of-major-depressive-disorder-mdd/ #BrainsWay #BWAY #IR #Neurotech #DeepTMS #Growth
0 · Reply
ZacksResearch
ZacksResearch Sep. 17 at 5:03 PM
$BWAY surges 11.9% on FDA clearance! 🚀 The new accelerated TMS protocol for depression is a game-changer, reducing treatment time significantly and boosting accessibility. This positions BrainsWay to capture more of the mental health market, driving strong growth potential. Discover the full impact here 👉 https://www.zacks.com/stock/news/2752844/bway-shares-gain-on-fda-nod-for-accelerated-deep-tms-depression-care?cid=sm-stocktwits-2-2752844-body-12865&ADID=SYND_STOCKTWITS_TWEET_2_2752844_BODY_12865
0 · Reply
ZacksResearch
ZacksResearch Sep. 17 at 4:03 PM
$BWAY popping on FDA green light 🚀🧠 Shares jumped after approval of its accelerated Deep TMS protocol, delivering faster depression care backed by strong clinical results. See the full details here 👉 https://www.zacks.com/stock/news/2752844/bway-shares-gain-on-fda-nod-for-accelerated-deep-tms-depression-care?cid=sm-stocktwits-2-2752844-teaser-12855&ADID=SYND_STOCKTWITS_TWEET_2_2752844_TEASER_12855
0 · Reply
notreload_ai
notreload_ai Sep. 16 at 4:13 PM
$BWAY has received FDA clearance for a new Deep TMS protocol, providing a non-invasive treatment for Major Depressive Disorder. This method targets deep brain areas to reduce treatment times. https://notreload.xyz/brainsway-deep-tms-accelerated-depression-treatment-approved/
0 · Reply
OpenOutcrier
OpenOutcrier Sep. 16 at 12:42 PM
$BWAY (+3.0% pre) BrainsWay gets FDA clearance for accelerated depression treatment protocol https://ooc.bz/l/77430
0 · Reply
BrainsWay
BrainsWay Sep. 16 at 8:01 AM
$BWAY 📊 BrainsWay by the Numbers: Strong Fundamentals for Growth BrainsWay (NASDAQ: BWAY) continues to advance its leadership in Deep TMS™ with solid financial guidance and a growing clinical and commercial footprint: • ~$52M Revenue (2025 guidance) • 75% Gross Margin (2025 guidance) • $7M Adjusted EBITDA (2025 guidance) • $78M Cash Balance (as of Q2 2025) • $62M Signed Backlog (Q2 2025) • 1,522 Total Installed Base (as of Q2 2025) • 880 OCD Systems (as of Q2 2025) • 6.3M Deep TMS™ Treatments delivered to 220K+ patients • 35+ Completed Clinical Trials with 360+ publications Each new deal BrainsWay has with leading mental health providers has the potential to add $10–15M in RPO with no additional operational expense, accelerating both top-line growth and margins. #BrainsWay #BWAY #InvestorRelations #Neurotech #DeepTMS
0 · Reply
BrainsWay
BrainsWay Sep. 10 at 4:17 PM
$BWAY BrainsWay is proud to exhibit at the 25th World Congress of Psychiatry (WCP 2025) in Prague, October 5–8. We’ll showcase our groundbreaking Deep TMS™ technology, advancing mental health treatment for depression, OCD, and addictions worldwide. Come meet us in Prague and discover how BrainsWay is shaping the future of psychiatry. 💡 #WCP2025 #BrainsWay #DeepTMS #MentalHealth
0 · Reply
BrainsWay
BrainsWay Sep. 8 at 1:26 PM
$BWAY BrainsWay closed a record-breaking quarter (Q2), reflecting strong demand for our noninvasive neurostimulation tech & commitment to advancing mental health care. Key Highlights: • Revenue: $12.6M, up 26% YoY • EBITDA: +40% YoY in H1 2025 • Net Profit: $2M, up 240% YoY • Performance Obligations: $62M, up 25% YoY • Cash Flow: 8 consecutive quarters of positive free cash flow • Guidance: Raised full-year 2025 Revenue and EBITDA outlook Operational Momentum: • 88 systems shipped in Q2 (+35% YoY); global installed base reached 1,522 systems • ~70% of recent customer engagements structured as multi-year lease agreements Strategic Partnerships: • Completed equity financings with Stella MSO and Axis MSO, two leading clinic networks Innovation Pipeline: • FDA submissions for accelerated MDD & adolescent depression protocols • PTSD expansion through collaboration with the Israel Ministry of Defense to support soldiers • BrainsWay continues to expand access, drive innovation, & lead in Deep TMS tech
0 · Reply
BrainsWay
BrainsWay Sep. 4 at 1:33 PM
$BWAY Welcome to the official BrainsWay ($BWAY) Investor Relations profile. Here you’ll find the latest news, financial updates, and official company announcements. We’re committed to keeping our shareholders informed, engaged, and confident in our vision.
0 · Reply
levilovelevi
levilovelevi Aug. 25 at 4:48 PM
2 · Reply
JarvisFlow
JarvisFlow Aug. 25 at 11:30 AM
HC Wainwright & Co. has adjusted their stance on BrainsWay ( $BWAY ), setting the rating to Buy with a target price of 17.
0 · Reply
ZacksResearch
ZacksResearch Aug. 22 at 6:40 PM
$BWAY's strategic move: Is the at-home mental health market the next big thing? 🤔 🧠 Invested $5M in Neurolief to expand reach with wearable neuromodulation tech 📈 Shares up 59% YTD; projected 88.9% earnings growth for the current year 🏠 Tapping into the at-home treatment space could diversify revenue & boost TAM Discover the full potential of this investment here 👉 https://www.zacks.com/stock/news/2741784/bway-shares-rise-on-strategic-investment-in-neuroliefs-at-home-care?cid=sm-stocktwits-2-2741784-body-9209&ADID=SYND_STOCKTWITS_TWEET_2_2741784_BODY_9209
0 · Reply
ZacksResearch
ZacksResearch Aug. 22 at 5:40 PM
$BWAY just expanded its mental health reach 🧠 A $5M strategic investment in Neurolief gives them exposure to at-home depression treatment — a major growth angle for the space. Full details here 👉 https://www.zacks.com/stock/news/2741784/bway-shares-rise-on-strategic-investment-in-neuroliefs-at-home-care?cid=sm-stocktwits-2-2741784-teaser-9208&ADID=SYND_STOCKTWITS_TWEET_2_2741784_TEASER_9208
0 · Reply
HorsePicks
HorsePicks Aug. 20 at 11:40 AM
$BWAY BrainsWay Invests $2.3M In Axis Mental Health Clinics With Option For $1M More
0 · Reply
Doozio
Doozio Aug. 18 at 9:11 PM
$BWAY or $LWAY 🐒🍌🧠⏰♾️
0 · Reply
JarvisFlow
JarvisFlow Aug. 14 at 6:07 PM
Northland Capital Markets has adjusted their stance on BrainsWay ( $BWAY ), setting the rating to Outperform with a target price of 15 → 19.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 14 at 6:06 PM
$BWAY Northland Capital Markets Maintains Outperform on BrainsWay, Raises Price Target to $19
0 · Reply
JarvisFlow
JarvisFlow Aug. 14 at 11:31 AM
HC Wainwright & Co. has updated their rating for BrainsWay ( $BWAY ) to Buy with a price target of 17.
0 · Reply